BioWorld

May 12, 2006

Avigen Adds $21M Privately To Focus On Neurology Products

With plans to expand the scope of its existing development programs, Avigen Inc. is raising $21.2 million through a private placement to institutional investors. (BioWorld Today) Read More

Genzyme, Angiotech Partner On Localized Cancer Therapy

New Models Hopefully Spell End Of One-Size-Fits-All Era

Diatos In-licensing Gilead's Kaposi's Drug DaunoXome

Other News To Note

Clinic Roundup

Appointments And Advancements

Today's news in brief

BioWorld

BioWorld briefs for Dec. 11, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 11, 2025.

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

DEE-lightful: Praxis’ phase II results allow stock to flex its muscle

BioWorld

Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...

Illustration of head with maze that is missing parts

CTAD 2025: The challenges of combination therapies for dementia

BioWorld Science

At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...